{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Adenocarcinoma&page=4", "query": { "condition": "Locally Advanced Adenocarcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 598, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Adenocarcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Adenocarcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T12:05:55.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04006522", "title": "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "89Zr-DFO-Atezolizumab", "type": "DRUG" }, { "name": "Positron Emission Tomography/Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "James Brugarolas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2019-10-02", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006522" }, { "nct_id": "NCT06381154", "title": "Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Endoscopic Ultrasound", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lymph Node Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photodynamic Therapy", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Verteporfin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-12-06", "completion_date": "2031-03-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06381154" }, { "nct_id": "NCT02315066", "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-04518600", "type": "DRUG" }, { "name": "PF-04518600 plus PF-05082566", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2015-04-23", "completion_date": "2020-11-12", "has_results": true, "last_update_posted_date": "2022-04-21", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 24, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315066" }, { "nct_id": "NCT01976741", "title": "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Rogaratinib (BAY1163877) oral solution", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) oral tablet", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) 800 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2013-12-30", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 3, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976741" }, { "nct_id": "NCT05512377", "title": "Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Solid Tumors", "Biliary Tract Cancer", "Lung Neoplasms", "Bladder Cancer" ], "interventions": [ { "name": "brigimadlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2022-12-13", "completion_date": "2025-09-25", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 18, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512377" }, { "nct_id": "NCT02761057", "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Papillary Renal Cell Carcinoma", "Metastatic Papillary Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2016-07-25", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 586, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02761057" }, { "nct_id": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Triple Negative Breast Cancer", "HR+/HER2- Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" }, { "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2016-12-19", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983045" }, { "nct_id": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "NSCLC", "HNSCC", "Melanoma", "TNBC", "Esophageal Cancer", "Gastric Cancer", "Cervical Cancer", "Colorectal Cancer", "Urothelial Carcinoma", "Clear Cell RCC", "HCC" ], "interventions": [ { "name": "Enzelkitug", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2022-10-20", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 10, "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05581004" }, { "nct_id": "NCT00004233", "title": "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2001-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 97, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004233" }, { "nct_id": "NCT02935309", "title": "Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Cancer", "Rectal Adenocarcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "External Radiation Therapy (XRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-10-14", "completion_date": "2020-05-14", "has_results": false, "last_update_posted_date": "2022-05-31", "last_synced_at": "2026-10-08T12:05:55.767Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935309" } ] }